A detailed history of Valley National Advisers Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Valley National Advisers Inc holds 122 shares of VRTX stock, worth $57,247. This represents 0.01% of its overall portfolio holdings.

Number of Shares
122
Previous 161 24.22%
Holding current value
$57,247
Previous $75,000 25.33%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$460.0 - $505.78 $17,940 - $19,725
-39 Reduced 24.22%
122 $56,000
Q2 2024

Jul 18, 2024

BUY
$392.81 - $485.53 $3,928 - $4,855
10 Added 6.62%
161 $75,000
Q1 2024

Apr 19, 2024

SELL
$407.69 - $446.08 $9,376 - $10,259
-23 Reduced 13.22%
151 $63,000
Q4 2023

Jan 25, 2024

BUY
$343.0 - $410.68 $14,749 - $17,659
43 Added 32.82%
174 $70,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $1,690 - $1,812
5 Added 3.97%
131 $46,000
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $1,095 - $1,222
4 Added 3.28%
126 $38,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $1,770 - $2,234
10 Added 8.93%
122 $27,000
Q3 2021

Nov 10, 2021

SELL
$181.39 - $202.99 $2,539 - $2,841
-14 Reduced 11.11%
112 $20,000
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $3,156 - $4,141
14 Added 12.5%
126 $37,000
Q2 2019

Aug 08, 2019

SELL
$164.61 - $190.37 $987 - $1,142
-6 Reduced 5.08%
112 $21,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $4,808 - $5,608
-33 Reduced 21.85%
118 $20,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $22,367 - $24,498
151
151 $23,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Valley National Advisers Inc Portfolio

Follow Valley National Advisers Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

News

Stay updated on Valley National Advisers Inc with notifications on news.